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Identification of Soluble Tumor Necrosis Factor-Like Weak
Inducer of Apoptosis (sTWEAK) as a Possible Biomarker of
Subclinical Atherosclerosis
Luis M. Blanco-Colio, Jose L. Martı´n-Ventura, Begon˜a Mun˜o´z-Garcı´a, Josune Orbe, Jose A. Pa´ramo,
Jean-Baptiste Michel, Alberto Ortiz, Olivier Meilhac, Jesu´s Egido
Objectives—Assessment of vascular risk in asymptomatic patients and the response to medical therapy is a major challenge
for prevention of cardiovascular events. Our aim was to identify proteins differentially released by healthy versus
atherosclerotic arterial walls, which could be found in plasma and serve as markers of atherosclerosis.
Methods and Results—We have analyzed supernatants obtained from cultured human carotid plaques and healthy arteries
by surface-enhanced laser-desorption/ionization time-of-flight mass spectrometry ProteinChip System. Surface-
enhanced laser-desorption/ionization analysis unveiled an 18.4-kDa peak released in lower amount by carotid plaques
than normal endarteries. This protein was identified as soluble tumor necrosis factor-like weak inducer of apoptosis
(sTWEAK). To confirm that sTWEAK was the protein of interest, Western blot and enzyme-linked immunosorbent
assay were performed. Both techniques confirmed that sTWEAK levels were decreased in carotid plaque supernatants.
Subsequent measurement of sTWEAK in plasma showed a reduced concentration in subjects with carotid stenosis
(N30) compared with healthy subjects matched by sex and age (N28) (P0.001). Furthermore, in a test population
of 106 asymptomatic subjects, we showed that sTWEAK concentrations negatively correlated with the carotid
intima-media thickness (r0.4; P0.001), an index of subclinical atherosclerosis.
Conclusions—These results suggest that sTWEAK could be a potential biomarker of atherosclerosis. (Arterioscler
Thromb Vasc Biol. 2007;27:916-922.)
Key Words: atherosclerosis  carotid arteries  plasma
Atherosclerotic plaque rupture is the trigger of cardiovas-cular complications such as myocardial infarction and
stroke, which represent the first cause of death in Western
countries.1 Atherogenesis is a complex process characterized
by lipid deposition and a chronic inflammatory response. The
resulting pathological vascular remodeling involves inflam-
matory cell recruitment, fibrosis, smooth muscle cell prolif-
eration, and neovascularization.2 Our hypothesis is that ath-
erosclerotic plaque prone to rupture could display a particular
profile of released proteins, reflecting directly the late events
preceding rupture such as proteolysis or cell death. The levels
of several inflammatory molecules in circulating blood have
been shown to be elevated in subjects at risk for an acute
coronary event.3–4 Most of existing markers were proposed
based on the assessment of proteins in plasma related to
inflammation process associated with atherosclerosis (eg,
C-reactive protein, CD40 ligand).5
We have recently reported a new strategy to identify
potential biological markers directly released by the arterial
wall, using a proteomic approach.6–7 Incubation of endarter-
ectomy samples versus control endarteries in a serum-free
culture medium allowed us to harvest separately the proteins
released from pathological and healthy areas and the super-
natants (conditioned media) were subsequently analyzed by
2-dimensional electrophoresis. After identification of the
differentially released proteins, their levels are measured in
plasma to assess their potential as biomarkers of atheroscle-
rosis. In this article, using a similar approach, we have
analyzed the conditioned media from normal mammary
endarteries versus carotid atherosclerotic endarterectomy
samples by surface-enhanced laser desorption ionization
(SELDI) time-of-flight (TOF) mass spectrometry (MS). This
method is based on the chromatographic fractionation of the
proteome on ProteinChips before MS analysis; it allows an
easy and quantitative comparison of profiles of proteins
released by atherosclerotic to those of control samples.8
Interestingly, the statistical validation of potential markers is
performed before their identification. SELDI TOF enabled us
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to compare hundreds of proteins in small volumes of
endartery-conditioned media. This technology, complemen-
tary to 2-dimensional electrophoresis, is particularly well-
suited for analysis of small (30 kDa) and potentially
under-represented proteins. Among the differentially released
proteins, we focused our attention on a 18.4-kDa protein
released in larger amounts by controls relative to carotid
plaques samples. This protein was identified as soluble tumor
necrosis factor-like weak inducer of apoptosis (sTWEAK).
More importantly, plasma levels of sTWEAK was measured
in a training population of 30 patients with carotid athero-
sclerosis and 28 healthy subjects, showing the same trend as
observed in conditioned media. Furthermore, sTWEAK was
assessed in a test population consisting of 106 asymptomatic
men in whom carotid artery intima/media thickness (IMT)
was used as a marker of subclinical atherosclerosis.9
Patients and Methods
Training Population (Patients With
Carotid Atherosclerosis)
Thirty consecutive patients (carotid stenosis 70%, 22 men, 8
women; age, 629 years; 86% with hypertension, 39% with diabe-
tes, 54% with hyperlipidemia) undergoing carotid endarterectomy at
our institutions were included. Plasma samples were collected from
patients before surgery and from 28 healthy volunteers (blood
donors) matched for age (598) and sex (21 men, 7 women).
Informed consent was obtained before enrolment. The study was
approved by the local Ethical Committees in accordance with
institutional guidelines.
Test Population (Asymptomatic Subjects)
The population studied consisted of 106 asymptomatic subjects (81
men, median age, 57 years [range, 25 to 78]) in whom global risk
assessment was performed in the course of a general health check-up
by Internal Medicine Department (University Clinic of Navarra,
Spain). In all subjects, absence of history of coronary disease, stroke
or peripheral arterial disease was recorded; additional exclusion
criteria were the presence of severely impaired renal function,
arteritis, connective tissue diseases, alcohol abuse, or use of nonste-
roidal anti-inflammatory drugs in the 2 weeks before entering the
study. The following conventional cardiovascular risk factors were
defined as previously described:10,11 arterial hypertension and/or use
of anti-hypertensive drugs; dyslipidemia and/or use of cholesterol-
lowering drugs, obesity, smoking, and diabetes and/or use of
pharmacological treatment. The local committee on human research
approved the study, which was performed in accordance with the
Declaration of Helsinki, and all participants gave written informed
consent. In all subjects, carotid ultrasonography was performed to
determine IMT, as previously described.9,11 Subjects were examined
by the same 2 sonographers blinded to all clinical information. The
reproducibility of IMT measurements between and within sonogra-
phers had previously been checked in 20 individuals who returned 2
weeks later for a second examination.9 The between-observer intra-
class correlation coefficient was 0.76 (P0.001) and the between-
subject repeatability was 0.82 (P0.001). The corresponding coef-
ficients of variance were 5% and 10%, respectively.
Obtention of Endartery Conditioned Media
Carotid endarterectomy samples and mammary arteries were dis-
sected and incubated as described previously.7 Conditioned media
were collected and centrifuged, and protein concentration was
determined by Bradford’s method. Tissue secretion attributed to
necrosis during the incubation period was 10% as assessed by
lactate dehydrogenase (LDH) release.7
SELDI TOF MS
Profiling of conditioned media from 7 mammary and 7 carotid
atherosclerotic plaques (20 micrograms) was performed using vari-
ous retention chromatography conditions: CM10 (cationic exchange
array), Q10 (anionic exchange array), IMAC (immobilized metal
affinity chromatography), and H50 (hydrophobic surface arrays).
Samples were incubated in a Bioprocessor (Ciphergen), and the
ProteinChip was then washed with the corresponding binding buffer
and with ultrapure water. The arrays were allowed to air-dry and 0.6
L of saturated solution of sinapinic acid in 50% v/v acetonitrile and
0.5% v/v trifluoroacetic acid was added twice to each spot. TOF of
the retained proteins was measured using a ProteinChip reader
(Ciphergen, PBS II). Validation was performed using this condition
on 23 additional samples of control mammaries and atherosclerotic
plaques. Calibration of SELDI-TOF was performed using all-in-one
Figure 1. Protein profiles of secretomes from
carotid plaques or mammary arteries. A, Mass
spectra showing a global protein profile of condi-
tioned media of 3 mammary (M1–M3) arteries ver-
sus 3 carotid (C1–C3) plaques on a CM10 Protein-
Chip pH5. The inset focuses on a peak of 18.4
kDa that is differentially released. B, SELDI quanti-
fication of 18.4-kDa protein secreted by mammary
arteries vs. carotid plaques. Results are represent-
ed as meanSD of log-normalized intensity.
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peptide standard (C100–0005; Ciphergen) before measurements of
all samples.
Isolation and Identification of the Marker
of Interest
Mammary secretomes were pooled and subjected to weak cation
exchange chromatography (CM10 spin columns; Ciphergen Biosys-
tems) using 100 mmol/L ammonium acetate pH5 as binding buffer.
The same procedure was performed in parallel, using carotid-
conditioned media containing nondetectable amounts of 18 400 m/z
peak. Elution was performed by washing with increasing pH buffers
(100 mmol/L Tris-HCl pH 7 to 10). The presence of the protein of
interest was monitored on NP20 ProteinChip array and eluted at
pH10. This elution fraction was concentrated and separated by
SDS-PAGE (12% NuPAGE, Invitrogen). After silver staining, the
band of interest (present in the pool of medium conditioned by
mammary endarteries but not in the conditioned medium from
complicated carotid plaques) was cut, destained, and dried. Gel
pieces were covered with a 10 ng/mL sequencing grade trypsin
(Sigma) in 50 mmol/L ammonium bicarbonate overnight at 37°C; 3
L of the digestion solution plus 1 L saturated CHCA (-cyano-
4-hydroxy-cinnamic acid) solution were added to H4 ProteinChip
arrays. Mass spectra obtained by SELDI TOF MS were compared
with those of blank gel pieces treated in the same conditions, and the
peak masses only present in the sample were exported to Mascot
(http://www.matrixscience.com), using the National Center for Bio-
technology Information and SwissProt databases.
Antigen–Antibody Capture
Analysis were performed on PS10 ProteinChips (Carbonyl DiImida-
zole activated amine surface). Each spot was coated with 0.5 g
protein G (diluted in 50 mmol/L NaHCO3), blocked with 0.5 mol/L
ethanolamine, and washed with phosphate-buffered saline containing
0.5% Triton X100 and 0.1% Triton X100. Then, 3 L of goat
anti-TWEAK (AF1090; R&D Systems) or goat IgG negative control
were applied on spots. After washing, equal amounts of conditioned
media from mammary and carotid endarteries were applied as
antigens. Then, the ProteinChip was washed in phosphate-buffered
saline containing 0.2% Triton X100 and rinsed in 10 mmol/L Hepes.
Finally, 0.6 L of sinapinic acid was applied twice and the array was
allowed to air-dry before the SELDI TOF reading.
Western Blot Analysis and
N-Deglycosylation Studies
When indicated, proteins obtained from conditioned media of mam-
mary arteries and atherosclerotic plaques in culture were incubated
with 1 U of PNGase F (G-5166; Sigma) overnight at 37°C. Equal
amounts of protein were loaded onto 12% acrylamide gels and
electrophoresed as previously described.7 Blots were incubated with
goat anti-TWEAK polyclonal antibody (AF1090; R&D Systems).
Enzyme-Linked Immunosorbent Assay
Venous blood samples from different subjects were collected on
EDTA. The whole-plasma samples were stored at 80°C until
analysis was performed. Plasma concentrations of sTWEAK were
determined in duplicate with commercially available enzyme-linked
immunosorbent assay kits (BMS2006INST; Bender MedSystems). A
total of 50 L of plasma samples was assayed in parallel to known
standard concentrations of recombinant TWEAK. The minimum
detectable level of TWEAK was 10 pg/mL. Intra- and inter-assay
coefficients of variation were 6.2% and 8.3%, respectively.
Immunohistochemistry
Specimens were fixed with paraformaldehyde and embedded in
paraffin, and immunohistochemistry was performed on 4-m-thick
pieces as described previously12 using goat anti-TWEAK polyclonal
antibody (AF1090; R&D Systems), anti-human -actin (Dako), or
anti-human CD68 (Dako).
Statistical Analysis
Statistical analysis was performed with SPSS for Windows software
package version 11.0 (SPSS Inc, Chicago, Ill). Enzyme-linked
immunosorbent assay data are expressed as medians and interquartile
ranges and were analyzed by the Mann-Whitney U test. Univariate
association was performed by Pearson correlation test. Multivariate
linear regression analysis was conducted with carotid IMT as
dependent variable, including in the model the traditional risk factors
and those variables that were significant in the univariate analysis. A
2-tailed P0.05 was considered statistically significant.
Results
In a first set of experiments, protein profiles were obtained for
7 mammary endartery-conditioned and 7 carotid-conditioned
media using different ProteinChip chromatographic surfaces
under various binding conditions. The most discriminating
condition (CM10, weak cationic exchange surface, pH5) was
used to test a total of 30 controls versus 30 carotid-
conditioned media. Figure 1A shows 6 representative spectra
obtained by analysis of conditioned media from mammary
versus atherosclerotic carotid endarteries, focusing on a peak
with a mass of 18.420 Da, which showed the highest
statistical differences between the 2 conditions. The intensity
of the 18.4-kDa peak, normalized to total ion current, was
Figure 2. Identification the 18.4-kDa peak as soluble TWEAK. A,
Sequence coverage of peptides resulting from trypsin digestion
of the 18.4-kDa peak. All matching peptides covered the
C-terminal region of TWEAK, corresponding to its soluble form.
The overall sequence coverage attains 56% of the theoretical
sequence of sTWEAK. B, Immunocapture of sTWEAK from
mammary or carotid samples. A polyclonal antibody against sol-
uble TWEAK was covalently coupled on preactivated Protein
Chip Arrays (PS10). sTWEAK was specifically captured from
mammary samples.
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5-fold higher in mammary relative to carotid atherosclerotic
conditioned medium (Figure 1B) (n30, P0.001). To
identify the protein of interest, cationic exchange chromatog-
raphy using CM10 spin columns in pH5 binding buffer was
performed on a pool of mammary conditioned media and on
conditioned medium from a carotid plaque, which did not
contain the peak of interest. The 18.4-kDa peak was eluted by
increasing the pH and monitored on NP20 ProteinChips. The
fraction containing the protein of interest (pool of mammary
conditioned media) and/or the similar fraction of carotid
conditioned medium were concentrated (SpeedVac) and
loaded onto a polyacrylamide gel. After comparison of the 2
profiles of proteins obtained on the silver-stained gel, the
band corresponding to the 18.4 kDa peak, only present in the
mammary samples, was cut and trypsin-digested. The prod-
ucts of trypsin digestion were analyzed using SELDI TOF
MS, and the masses obtained for these peptides were exported
to Mascot database (http://www.matrixscience.com) (Figure
2A). We found that the peptide masses obtained matched with
those of the soluble form of TWEAK, digested in silico by
trypsin, with a probability-based Mowse score of 76 (access
number O43508). TWEAK also designated that Apo-3 Li-
gand has an expected molecular mass of 27.5 kDa; however,
a soluble form of 18 kDa has been reported to be a secreted
ligand belonging to the tumor necrosis factor superfamily.13
All matching peptides resulting from trypsin digestion cov-
ered the C-terminal region of TWEAK, corresponding to its
soluble form. The overall sequence coverage attains 56% of
the theoretical sequence of soluble TWEAK. These findings
were consistent with the expected molecular mass of
sTWEAK and a possible retention on a cationic exchange
surface (at pH5, the protein is positively charged because its
pI is 9.5). To confirm that the 18.4-kDa protein detected by
the SELDI TOF is sTWEAK, capture experiments were
performed on PS10 ProteinChips coated with protein G, using
either goat anti-TWEAK or nonimmune goat IgGs. As
depicted in the Figure 2B, the 18.4-kDa protein was captured
by the anti-TWEAK antibody (directed against the extracel-
lular domain of TWEAK) from the pool of mammary
conditioned media, but not by the IgG control or in the
carotid-conditioned medium.
To further confirm that sTWEAK is differentially released
by control and atherosclerotic plaques, we have analyzed the
secretomes of carotid endarterectomy samples versus control
mammary arteries by Western blot and enzyme-linked im-
munosorbent assay using antibodies directed against the
extracellular domain of TWEAK. Western blot analysis
showed 2 different bands of 18 and 25 to 26 kDa, for which
intensities were increased in control arteries relative to
atherosclerotic plaques (Figure 3A). It is known that there is
a consensus N-glycosylation site in soluble TWEAK at
position 139 and that the glycosylated form of TWEAK has
a molecular weight of 25 to 26 kDa.14 Incubation of
mammary secretomes with PNGase F, which efficiently
N-deglycosylates proteins, induces a diminution of the 25 to
26 kDa band, indicating that this band should be the glyco-
sylated form of TWEAK (Figure 3B). Quantification of
sTWEAK by enzyme-linked immunosorbent assay confirmed
that atherosclerotic plaques released less sTWEAK than
control mammary arteries (43.6 pg/mL [27.8 to 67.2] and
Figure 3. TWEAK expression and release by mam-
mary arteries and carotid plaques. A, Representa-
tive Western blot for sTWEAK in conditioned media
samples (M, mammary artery; C, carotid plaque).
Gly-TWEAK, glycosylated TWEAK. B, Western blot
showing the effect of PNGase F on glycosylated
TWEAK. C, Enzyme-linked immunosorbent assay
of sTWEAK on conditioned media from mammary
or carotid plaques (sTWEAK concentrations was
normalized by protein concentration). D, TWEAK
expression in human arteries. Immunohistochemis-
try showing the expression of TWEAK and localiza-
tion of smooth muscle cells and macrophages in
serial section from human carotid atherosclerotic
plaques. Magnification 400.
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116.9 pg/mL [96.2 to 179.5], respectively) (Figure 3C).
Furthermore, we assessed the presence of total TWEAK by
immunohistochemistry in nonincubated tissues and showed
that mammary arteries display a strong positivity for
TWEAK relative to carotid plaques (not shown). Further-
more, TWEAK colocalizes with macrophages and smooth
muscle cells in atherosclerotic plaques (Figure 3D).
To verify our hypothesis that plasma content can reflect
arterial wall secretion, we have used a training set of plasma
samples from patients with carotid atherosclerosis (stenosis
70%; n30) and healthy subjects (n28) matched by sex
and age. We have observed that sTWEAK was diminished in
atherosclerotic patients as compared with healthy subjects
(202.6 pg/mL [148.1 to 239.9] versus 393.24 pg/mL [367.1 to
481.07], respectively; P0.001) (Figure 4A).
To validate sTWEAK as a potential marker of atheroscle-
rosis, it was assessed in plasma of a test population consisting
of 106 asymptomatic subjects in whom IMT was measured.
Characteristics of the studied population are summarized in
Table 1. When we analyzed tertiles of sTWEAK there was a
linear trend correlating the reduction of sTWEAK and the
increase in carotid IMT (P0.001). In addition, as shown in
the Figure 4B, a univariate analysis shows an inverse corre-
lation between sTWEAK and IMT (r0.402; P0.001).
Furthermore, only marginal inverse correlations could be
observed between sTWEAK and C-reactive protein
(r0.18) or glucose concentrations (r0.19) (Table 2).
Correlation between sTWEAK and IMT was superior to
those observed between IMT and other clinical and labora-
tory parameters analyzed including C-reactive protein, a
marker of systemic inflammation3 (Table 2). Interestingly,
the association between sTWEAK and carotid IMT remained
significant after adjusting for traditional risk factors and
inflammatory markers (Table I, please see http://atvb.
ahajournals.org).
Discussion
SELDI TOF MS is a recently described affinity-based MS
method combining chromatography and MS. ProteinChip
technology has proven to be useful in the discovery of
potential diagnostic markers of different types of cancer, such
as ovarian cancer.15 However, its use to discover new
biomarkers related to atherosclerotic diseases has not been
reported yet. We have previously validated an original
approach analyzing the secreted proteomes from atheroscle-
rotic plaques and nonpathological arterial wall for which
incubation of the tissue in a serum-free medium allows the
accumulation of proteins and their subsequent analysis with-
out interference with plasma proteins.7 In the present study, to
identify potential biomarkers reflecting the presence of com-
plicated atherosclerotic plaques, protein profiling was per-
formed on secretomes from endarterectomy samples com-
pared with control endarteries by SELDI TOF MS. Although
the use of healthy carotid arteries to compare with patholog-
Figure 4. Plasma levels of sTWEAK in human subjects. A,
Plasma levels of sTWEAK in atherosclerotic patients (n30) and
healthy controls (n28). Boxes represent 25th and 75th percen-
tiles; line within boxes, median. Error bars mark 10th and 90th
percentile. B, Correlation between IMT and sTWEAK in asymp-
tomatic individuals. The IMT of common carotid arteries nega-
tively correlates with sTWEAK concentration (r0.402;
P0.001).
TABLE 1. Baseline Clinical Characteristics of the
Studied Populations
Total Population (n106)
Age, y 57.312.0
Sex, male/female 81/25
Smokers, yes/no 33/73
BMI, kg/m2 27.93.8
SBP, mm Hg 132.523.1
DBP, mm Hg 81.710.5
Arterial hypertension, yes/no 58/48
Diabetes mellitus, yes/no 18/88
Glucose, mg/dL 106.934.2
Total cholesterol, mg/dL 218.438.8
HDL cholesterol, mg/dL 49.713.6
LDL cholesterol, mg/dL 146.134.3
Triglycerides, mg/mL 320.190.3
CRP*, mg/L 4.70.7
Fibrinogen, mg/dL 320.190.3
vWF, % 124.272.6
sTWEAK, pg/mL 199.240.5
Mean carotid IMT, mm 0.750.2
Values are expressed as meanSD, N of subjects, and *meanSEM.
BMI indicates body mass index; CRP, C-reactive protein; DBP, diastolic blood
pressure; IMT, intima-media thickness; SBP, systolic blood pressure; vWF, von
Willebrand factor.
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ical carotid arteries would be more appropriate, it was not
possible for us to obtain this type of samples. For this reason,
we have used normal mammary arteries in our study.
The analysis of protein profiles led us to the identification
of soluble TWEAK as being more released by control versus
atherosclerotic endarteries. Because of the limitations of
SELDI TOF as a screening tool,8 we have extensively
validated our results by other different techniques such as
immunocapture, Western blot, and enzyme-linked immu-
nosorbent assay. All these techniques confirmed that
sTWEAK was secreted in a lesser amount by carotid athero-
sclerotic plaques. Interestingly, the same trend was observed
in plasma showing a decreased level of sTWEAK in carotid
stenosis patients relative to control subjects. TWEAK has
been identified as a secreted ligand belonging to the tumor
necrosis factor superfamily.13 TWEAK is expressed as a type
II transmembrane protein that can be proteolytically pro-
cessed to generate a soluble cytokine.16 It is unknown
whether the membrane-bound form of TWEAK is biologi-
cally active, albeit its soluble form was shown to induce
various biological effects in cell culture, such as the expres-
sion of chemoattractant proteins (MCP-1 and IL-817) and
matrix metalloproteinase-9,18 or to activate NF-kB signal
transduction pathway,19 known to be a key regulator of
numerous inflammatory response genes. In this respect, we
have previously observed that recombinant TWEAK can
induce MCP-1 in human aortic smooth muscle cells in
culture.20 TWEAK was reported to be expressed in human
carotid atherosclerotic macrophages,18 but no comparison
with healthy arteries was shown in that study. We have
previously demonstrated that mammary arteries display a
strong positivity for TWEAK relative to carotid plaques20 in
accordance with our results obtained in conditioned media.
Moreover, TWEAK seems to be expressed in nonpathologi-
cal conditions by various organs and cells including smooth
muscle cells.16 We have also observed that sTWEAK was
diminished in atherosclerotic patients as compared with
healthy subjects, indicating that plasma sTWEAK concentra-
tions could reflect arterial wall secretion. Although our results
seem to be contradictory at the first glance because TWEAK
has been related with proinflammatory response, it has been
reported recently that TWEAK may have evolved to guard
against the development of a potentially harmful excessive
inflammatory response.21 Furthermore, it has been also re-
ported that under proinflammatory conditions, TWEAK ex-
pression is downregulated,22 which is in agreement with our
observation that TWEAK is expressed and released in lesser
amounts by atherosclerotic lesions.
Measurement of carotid wall thickening is widely believed
to be a valuable index of atherosclerosis. The predictive value
of increased IMT for future cardiovascular events is clearly
demonstrated in different studies.23 In our study, we have
observed a negative correlation between sTWEAK and IMT
in asymptomatic subjects, indicating that low levels of this
protein could be a potential index of atherosclerosis. In
addition, sTWEAK concentration was not associated with
lipid profile or other surrogate markers of atherosclerosis
such as von Willebrand factor (marker of endothelial dys-
function),24 fibrinogen,25 or C-reactive protein. Moreover, the
association between sTWEAK and IMT remained significant
after adjusting for inflammatory markers and traditional
cardiovascular risk factors, indicating that sTWEAK could be
an independent marker of atherosclerosis. In the same con-
text, expression of other members of the tumor necrosis factor
superfamily is modulated in subjects with high cardiovascular
risk factors. Whereas Fas ligand could be actively participat-
ing in atherosclerotic disease,26 soluble Fas ligand concentra-
tions are diminished in patients with combined familial
hyperlipidemia, carotid atherosclerosis,12 and in subjects at
high cardiovascular risk.27 Furthermore, tumor necrosis
factor-related apoptosis-inducing factor ligand are also de-
creased in subjects with acute coronary syndrome.28 More
studies on large cohorts are needed to validate sTWEAK as a
marker of subclinical atherosclerosis.
Finally, it is important to note that it is the first time to our
knowledge that sTWEAK is measured in human plasma. This
protein can be related with different pathological situations,
such as cancer29 or immune diseases,30 and screening of
sTWEAK in plasma from patients with different pathologies
would give important information on its specificity as a
negative marker of atherosclerosis.
In conclusion, we have identified sTWEAK as a potential
marker of atherothrombosis released by control arteries in
larger amount than by carotid plaques. Measurement of
sTWEAK in plasma showed that it is decreased in patients
with carotid atherosclerosis relative to healthy subjects.
Finally, sTWEAK is inversely correlated with IMT in asymp-
tomatic patients, indicating that this protein is a potential
systemic biomarker of subclinical atherosclerosis.
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TABLE 2. Correlation Coefficients of Mean IMT and sTWEAK
With Clinical and Laboratory Parameters in the
Studied Population
IMT sTWEAK
r P r P
Age, y 0.35 0.001 0.01 0.91
BMI, kg/m2 0.17 0.06 0.06 0.53
SBP, mm Hg 0.35 0.001 0.14 0.14
DBP, mm Hg 0.04 0.68 0.02 0.79
Glucose, mg/dL 0.25 0.007 0.19 0.04
Cholesterol, mg/dL 0.003 0.97 0.18 0.07
Triglycerides, mg/dL 0.07 0.46 0.01 0.87
LDL cholesterol, mg/dL 0.004 0.96 0.14 0.14
HDL cholesterol, mg/dL 0.15 0.11 0.09 0.35
Log CRP 0.16 0.09 0.18 0.059
Fibrinogen, mg/dL 0.29 0.001 0.05 0.58
vWF, % 0.21 0.03 0.08 0.38
sTWEAK, pg/mL 0.402 0.001 — —
Correlations and P values from Pearson correlation coefficient.
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Table I (online): Multiple linear regression analysis with carotid IMT as dependent variable.  
 
  B SE (B) Partial R2 (%) p 
IMT (mm) sTWEAK, pg/mL 0,013 0,001 -30.0 0.003 
 Age, years 0.057 0.001 37.3 0.001 
 Smoking 0,117 0,041 30.3 0.003 
 
 
B: regression coefficient; SE (B): standard error; R2: partial correlation coefficient after adjustment.  
Adjusted for age, gender, smoking, BMI, glucose, total cholesterol, systolic blood pressure, fibrinogen, 
von Willebrand and CRP. 
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